Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 500-508

  Zhang, Li ^a   Cao, Zeng ^a   Zou, Yao ^a   Ruan, Min ^a   Li, Qinghua ^a   Wang, Jianxiang ^a   Zhu, Xiaofan ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Acute promyelocytic leukemia; Children; Outcome; PML RARa; RQ PCR

Indexed keywords

ARSENIC TRIOXIDE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FUSION GENE; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PML RARA GENE; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ARSENICALS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; OXIDES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TRETINOIN;

EID: 84862882135     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1034-9     Document Type: Article

References (29)

1. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-91.
2. Zhang L, Zhu X, Zou Y, Chen Y, Chen X. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. Int J Hematol. 2011;93: 199-205.
3. Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27:2668-76.
4. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide- based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342-7.
5. Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115:1690-6.
6. Grimwade D, Tallman MS. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Res. 2011;35:3-7.
7. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106:447-53. (Pubitemid 40981236)
8. Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005;23:7632-40. (Pubitemid 46291827)
9. Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol. 2011;152:89-98.
10. Creutzig U, Zimmermann M, Dworzak M, Urban C, Henze G, Kremens B, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol. 2010;149:399-409
11. Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematol. 2008;119:73-82. (Pubitemid 351606165)
12. de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22:1404-12. (Pubitemid 41103622)
13. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter AIDA trial. GIMEMA-AIEOP Multicenter AIDA Trial. Blood. 1998;92:784-9. (Pubitemid 28355460)
14. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet. 1992;340:1437-8.
15. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia. 1996;10:61-6. (Pubitemid 26052981)
16. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol. 2002;15: 137-58.
17. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol. 2008;35:388-400.
18. Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica. 2007;92:315-22.
19. Lee S, Kim YJ, Eom KS, Min CK, Kim HJ, Cho SG, et al. The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. Haematologica. 2006;91: 671-4. (Pubitemid 43799467)
20. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650-8.
21. Cassinat B, de Botton S, Kelaidi C, Ades L, Zassadowski F, Guillemot I, et al. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leuk Res. 2009;33:1178-82.
22. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-9. (Pubitemid 46594039)
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-9. (Pubitemid 17064313)
24. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-28.
25. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia. 2003;17:2474-86. (Pubitemid 38072587)
26. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17:2318-57. (Pubitemid 38072573)
27. Douer D, Santillana S, Ramezani L, Samanez C, Slovak ML, Lee MS, et al. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. Br J Haematol. 2003;122:563-70. (Pubitemid 36995211)
28. Dong S, Geng JP, Tong JH, Wu Y, Cai JR, Sun GL, et al. Breakpoint clusters of the PML gene in acute promyelocytic leukemia: primary structure of the reciprocal products of the PML-RARA gene in a patient with t(15;17). Genes Chromosomes Cancer. 1993;6:133-9. (Pubitemid 23079554)
29. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, et al. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1995;9:1478-82.